Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Form
424B5
Filing Date
Dec 11, 2017
Document Date
Dec 11, 2017
Form Description
Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3
Filing Group
Registration Statements
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp